Psychedelics such as psilocybin and MDMA show promise for treating mood disorders, PTSD, prolonged grief, and psychological distress from serious illness in older adults, and may aid dementia patients or promote personal growth in healthy seniors. Both compounds act on the 5HT2A receptor and can be safely given to healthy adults under controlled conditions, but they raise blood pressure and heart rate, posing risks for older adults with cardiovascular disease. Few older adults or those with multiple health conditions have been included in clinical trials, limiting generalizability. More research is needed on safety and efficacy in this population.
Group psilocybin-assisted therapy may help older long-term AIDS survivor gay men accept death, dying, and impermanence, as well as their illness and complex emotions. This secondary qualitative analysis of interviews from six participants found three major themes: acceptance of death, acceptance of illness, and embracing complex emotions. The findings suggest that the therapy fosters death acceptance by helping participants accept their illness and engage with the full range of emotions that arise when facing mortality. Further studies are needed to validate these results, which highlight the importance of focusing on death acceptance in psychedelic research with seriously ill populations.